$385 Million is the total value of MPM BioImpact LLC's 31 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 12.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | $78,241,782 | -3.0% | 7,648,268 | 0.0% | 20.33% | -2.9% | |
| PRVB | Buy | Provention Bio Inc | $28,288,797 | +197.9% | 1,173,809 | +30.6% | 7.35% | +198.3% |
| ISEE | Sell | Iveric Bio Inc | $25,441,662 | +12.1% | 1,045,691 | -1.3% | 6.61% | +12.3% |
| ITOS | iTeos Therapeutics, Inc. | $23,762,284 | -30.3% | 1,745,943 | 0.0% | 6.17% | -30.2% | |
| INBX | Sell | Inhibrx, Inc Com | $22,498,342 | -29.0% | 1,192,281 | -7.3% | 5.84% | -28.9% |
| NTLA | Buy | Intellia Therapeutics, Inc. | $21,335,547 | +34.3% | 572,459 | +25.7% | 5.54% | +34.5% |
| RLAY | New | Relay Therapeutics Inc. | $20,186,192 | – | 1,225,634 | +100.0% | 5.24% | – |
| GERN | Sell | Geron Corporation | $18,231,396 | -11.0% | 8,401,565 | -0.8% | 4.74% | -10.9% |
| RETA | Sell | Reata Pharmaceuticals inc-a | $16,544,794 | +124.3% | 176,874 | -8.9% | 4.30% | +124.6% |
| RPTX | Repare Therapeutics, Inc. | $16,136,114 | -33.1% | 1,639,849 | 0.0% | 4.19% | -33.0% | |
| IOVA | Buy | Iovance Biotherapeutics Inc Com | $15,977,509 | +16.3% | 2,614,977 | +21.7% | 4.15% | +16.5% |
| RGNX | Sell | REGENXBIO Inc. | $11,680,159 | -17.1% | 617,671 | -0.6% | 3.03% | -17.0% |
| VERV | Sell | Verve Therapeutics, Inc | $11,586,484 | -26.0% | 803,501 | -0.6% | 3.01% | -25.8% |
| MDGL | Buy | Madrigal Pharmaceuticals inc | $8,730,566 | +12.4% | 36,038 | +34.6% | 2.27% | +12.5% |
| TVTX | Buy | Travere Therapeutics Inc. | $7,053,809 | +19.1% | 313,642 | +11.3% | 1.83% | +19.3% |
| QURE | Sell | Uniqure N.V. | $7,013,231 | -67.1% | 348,224 | -63.0% | 1.82% | -67.0% |
| INSM | Sell | Insmed Incorporated | $6,806,224 | -17.0% | 399,192 | -2.7% | 1.77% | -16.9% |
| HOWL | Werewolf Therapeutics, Inc. | $6,208,829 | +26.8% | 2,388,011 | 0.0% | 1.61% | +27.0% | |
| CRNX | Sell | Crinetics Pharmaceuticals Inc. | $5,787,896 | -14.9% | 360,392 | -3.0% | 1.50% | -14.7% |
| RVMD | Buy | Revolution Medicines, Inc. | $5,350,497 | +50.7% | 247,022 | +65.7% | 1.39% | +50.9% |
| TCRR | TCR2 Therapeutics, Inc. | $5,056,473 | +50.2% | 3,370,982 | 0.0% | 1.31% | +50.3% | |
| KDNY | Buy | Chinook Therapeutics, Inc. | $4,579,209 | +118.5% | 197,806 | +147.3% | 1.19% | +118.8% |
| AXSM | Buy | Axsome Therapeutics, Inc. | $4,342,395 | +8.3% | 70,402 | +35.5% | 1.13% | +8.5% |
| FOLD | Sell | Amicus Therapeutics Inc. | $4,306,158 | -11.9% | 388,292 | -3.0% | 1.12% | -11.8% |
| ARQT | Sell | Arcutis Biotherapeutics inc | $2,795,507 | -27.9% | 254,137 | -3.0% | 0.73% | -27.8% |
| HARP | Harpoon Therapeutics, Inc. | $2,378,350 | +2.5% | 3,196,707 | 0.0% | 0.62% | +2.7% | |
| PHAT | Buy | Phathom Pharmaceuticals inc | $1,518,071 | -30.9% | 212,615 | +8.5% | 0.39% | -30.9% |
| INZY | Buy | Inozyme Pharma Inc. | $1,339,261 | +453.4% | 233,728 | +1.4% | 0.35% | +452.4% |
| ONCR | Oncorus, Inc. | $817,699 | +36.0% | 2,377,031 | 0.0% | 0.21% | +35.9% | |
| AVRO | AVROBIO, Inc. | $647,918 | +40.3% | 647,918 | 0.0% | 0.17% | +40.0% | |
| BDTX | Black Diamond Therapeutics, Inc. | $273,838 | +5.0% | 144,888 | 0.0% | 0.07% | +4.4% | |
| PRAX | Exit | Praxis Precision Medicines Inc. | $0 | – | -610,000 | -100.0% | -0.38% | – |
| GTHX | Exit | G1 Therapeutics, Inc. | $0 | – | -650,000 | -100.0% | -0.92% | – |
| HRMY | Exit | Harmony Biosciences Hldgs Inc. | $0 | – | -139,377 | -100.0% | -1.99% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.